autologous anti-bcma car t-cells phe885
Generic: Autologous Anti-BCMA CAR T-cells PHE885
autologous anti-bcma car t-cells phe885: 1 clinical trial tracked.
autologous anti-bcma car t-cells phe885 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about autologous anti-bcma car t-cells phe885, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Multiple Myeloma
Primary endpoint: Incidence of Dose limiting toxicities (DLT)
Interventionalopen96 enrolledStarted 2020-07Completion 2025-049 sites · Australia, Israel, Singapore, United StatesNovartis Pharmaceuticals